Veradermics (MANE) Capital Expenditures (2025 - 2026)

Veradermics (MANE) posted Capital Expenditures of $174000.0 for Q1 2026, up 815.79% on a QoQ basis from $19000.0 in Q1 2025, and up 815.79% year-over-year from $19000.0 in Q1 2025.

Veradermics (MANE) Capital Expenditures (2025 - 2026) Analysis & Trends

Veradermics' Capital Expenditures history runs 2 years deep, the most recent figure standing at $174000.0 for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -8,939.03
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 43.25 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 133.40 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 230.60 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 786,000.00
10 Veradermics 2.63 Bn 2.63 Bn - 174,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 174,000.00
Mar 31, 2026 174,000.00
Mar 31, 2025 19,000.00
Mar 31, 2025 19,000.00